title: Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study.
abstract: OBJECTIVE
  This study aims to assess use of hormone therapy (HT) after cervical cancer treatment in women of premenopause age.
  
  
  METHODS
  We identified 837 women aged 45 years or younger at diagnosis of cervical cancer in the Swedish Cancer Register from January 1, 2005 to September 30, 2009 with a minimal follow-up of 1.5 years. Information on cancer treatment (surgical operation, radiotherapy, and/or chemotherapy) was obtained through the National Patient Register. Use of HT was estimated through HT dispensing during follow-up as recorded in the Prescribed Drug Register. Percentage of recommended dose was assessed by frequency of HT dispensing at half-year intervals up to April 1, 2011 or a maximal age of 50 years.
  
  
  RESULTS
  A total of 257 women (31%) received acute estrogen deprivation due to bilateral salpingo-oophorectomy and/or radiotherapy. Among these women, 171 (67%) of 257 had at least one dispensing of HT during the period 0.5 to 1 year after diagnosis, and 118 (46%) of 257 were dispensed 75% or more of the recommended dose. Proportion users decreased to 39% at 4.5 to 5 years after diagnosis (21% with ≥ 75% of the recommended dose). Women younger than 40 years had a higher prevalence of HT use at 0.5 to 1 year (79%), decreasing to 45% after 4.5 to 5 years. The results did not vary by cancer histology.
  
  
  CONCLUSIONS
  Fewer than half of cervical cancer survivors with therapy-induced early menopause used HT at or close to the recommended dose, and the use decreased during follow-up. Increased awareness of the health benefits of HT for this patient group is needed among professionals and women.
authors.affiliation: From the 1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; 2Department of Oncology, Sahlgrenska Academy, Gothenburg, Germany; 3Center for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; 4Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; and 5Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Åsa Hallqvist
authors.initials: ÅH
authors.lastname: Everhov
authors.forename: Tommy
authors.initials: T
authors.lastname: Nyberg
authors.forename: Karin
authors.initials: K
authors.lastname: Bergmark
authors.forename: Anna
authors.initials: A
authors.lastname: Citarella
authors.forename: Angelique Flöter
authors.initials: AF
authors.lastname: Rådestad
authors.forename: Angelica Lindén
authors.initials: AL
authors.lastname: Hirschberg
authors.forename: Karin E
authors.initials: KE
authors.lastname: Smedby
mesh_terms: D000328:Adult; D059248:Chemoradiotherapy / Q000379:methods; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008875:Middle Aged; D017697:Premenopause; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012042:Registries; D013548:Sweden / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016387:Women's Health
chemical_list: D004967:Estrogens